Technical Analysis for PFE - Pfizer, Inc.

Grade Last Price % Change Price Change
B 54.125 1.09% 0.59
PFE closed down 1.05 percent on Wednesday, January 19, 2022, on 53 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Feb 8
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical PFE trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 1.09%
MACD Bearish Centerline Cross Bearish 1.09%
Strong but Oversold Other 1.09%
Inside Day Range Contraction 1.09%
Down 3 Days in a Row Weakness 1.09%
Down 4 Days in a Row Weakness 1.09%
Down 5 Days in a Row Weakness 1.09%
Oversold Stochastic Weakness 1.09%
Fell Below 50 DMA Bearish 0.03%
Stochastic Reached Oversold Weakness 0.03%
Older End-of-Day Signals for PFE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout 9 minutes ago
Up 1% 42 minutes ago
Fell Below Previous Day's Low about 3 hours ago
Lower Bollinger Band Support about 3 hours ago
Possible Inside Day about 23 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Pfizer, Inc. Description

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care physicians for Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation therapeutic and disease areas. The company's Specialty Care and Oncology segment provides human prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. Its Established Products and Emerging Markets segment offers human prescription pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions, as well as that are sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. The company's Animal Health segment offers products and services to prevent and treat disease in livestock and companion animals, including anti-infectives, vaccines, parasiticides, medicinal feed additives, other pharmaceutical products, and other non-pharmaceutical products. Its Consumer Healthcare segment provides non-prescription products in therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. has a strategic collaboration with CytomX Therapeutics, Inc. to develop and commercialize Multiple Probody drug conjugates in oncology. The company was founded in 1849 and is headquartered in New York, New York.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Biopharmaceutical Disease Pharmaceutical Industry Pain Clinic Medication Pharmaceutical Products Inflammation Neuroscience Alzheimer's Disease Hypertension Ophthalmology Animal Health Dysfunction Dietary Supplement Pain Management Pulmonary Arterial Hypertension Major Depressive Disorder Primary Care Smoking Depressive Disorder Hemophilia Smoking Cessation Anti Infectives Endocrine Disorders Livestock Producers Prescription Product Prescription Products Erectile Dysfunction Cardiovascular Genitourinary

Is PFE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 61.71
52 Week Low 33.36
Average Volume 41,614,001
200-Day Moving Average 45.06
50-Day Moving Average 54.35
20-Day Moving Average 56.73
10-Day Moving Average 55.39
Average True Range 1.70
ADX 20.54
+DI 18.78
-DI 26.73
Chandelier Exit (Long, 3 ATRs) 56.61
Chandelier Exit (Short, 3 ATRs) 58.53
Upper Bollinger Bands 60.36
Lower Bollinger Band 53.10
Percent B (%b) 0.06
BandWidth 12.81
MACD Line -0.05
MACD Signal Line 0.56
MACD Histogram -0.6076
Fundamentals Value
Market Cap 297.6 Billion
Num Shares 5.56 Billion
EPS 1.54
Price-to-Earnings (P/E) Ratio 34.81
Price-to-Sales 4.22
Price-to-Book 3.11
PEG Ratio 5.22
Dividend 1.52
Dividend Yield 2.84%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 55.10
Resistance 3 (R3) 55.24 54.87 54.84
Resistance 2 (R2) 54.87 54.47 54.80 54.75
Resistance 1 (R1) 54.20 54.22 54.02 54.06 54.67
Pivot Point 53.83 53.83 53.73 53.76 53.83
Support 1 (S1) 53.16 53.43 52.98 53.02 52.41
Support 2 (S2) 52.79 53.18 52.72 52.33
Support 3 (S3) 52.12 52.79 52.24
Support 4 (S4) 51.98